Amphotericin B (MAT2203)

Small molecule

On holdsponsor decision

Evidence outlook · program status

On hold (2024-10-31), as a strategic decision by the sponsor

Matinas ceased all product development in October 2024 after partnership talks ended and seeks a partner or buyer for MAT2203; the Phase 3 ORALTO trial never started. The trials below are the program's evidence history; no evidence signal is assigned while development is paused.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Cryptococcal Meningitis
Phase 2 (4)
Other / comorbidity
NCT02629419 · Matinas BioPharma Nanotechnologies, Inc.
2016-09-27 – 2022-08-06 · Candidiasis, Chronic Mucocutaneous
What this study did
NCT03187691 · Matinas BioPharma Nanotechnologies, Inc.
2019-08 – 2020-12 · Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
What this study did
NCT03167957 · Matinas BioPharma Nanotechnologies, Inc.
2019-12 – 2020-12 · Vulvovaginal Candidiases, Yeast Infection, Vulvovaginitis, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
What this study did
NCT02971007 · Matinas BioPharma Nanotechnologies, Inc.
2016-11 – 2017-05 · Vulvovaginitis, Yeast Infection, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
What this study did
Phase 1/2 (2)
Cryptococcal Meningitis
NCT04031833 · Matinas BioPharma Nanotechnologies, Inc.
2019-10-24 – 2023-02-15 · Cryptococcal Meningitis
What this study did
Other / comorbidity
NCT03196921 · Matinas BioPharma Nanotechnologies, Inc.
2018-10-01 – 2020-03-01 · Cryptococcal Infections
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

10 July 2026Licensing dealMatinas agrees to sell the MAT2203 subsidiary to Azurity
Matinas BioPharma; Azurity Pharmaceuticals · Source ↗